OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
Rhea-AI Summary
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharma focused on neuropathic corneal pain and anterior segment eye diseases, will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium.
The virtual event is scheduled for Thursday, July 9, 2026 at 8:30 AM ET, featuring CEO Robert J. Dempsey and CMO Flavio Mantelli, moderated by Biren Amin of Piper Sandler.
Positive
- None.
Negative
- None.
Market reaction after Piper Sandler ophthalmology fireside chat: OKYO +8.70% in the Jul 7 session
In the Jul 7 session, OKYO gained 8.70%, reflecting a notable positive market reaction. Argus tracked a peak move of +23.8% during that session. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 6.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Advisory board appointment | Positive | -0.0% | Appointment of international ophthalmology expert to Scientific Advisory Board. |
| Apr 29 | Conference participation | Positive | -3.8% | CEO and CSO presentations at May scientific conferences on urcosimod data. |
| Apr 07 | Data presentation | Positive | +1.9% | Planned Phase 2 urcosimod data presentation and SAB meeting at ASCRS. |
| Mar 19 | Insider share purchase | Positive | +0.0% | Director Brancaccio purchased additional ordinary shares on NASDAQ. |
| Mar 19 | Insider share purchase | Positive | +0.0% | Executive chairman-related entity acquired additional ordinary shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OKYO news on management, conferences, and insider activity has produced mostly mild, mixed price reactions.
Key Terms
neuropathic corneal pain medical
anterior segment medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Piper Sandler Virtual Ophthalmology Symposium being held on Thursday, July 9, 2026.
Details of the event are as follows:
Presenters: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer
Date/Time: Thursday, July 9 at 8:30 AM ET
Moderator: Biren Amin, Managing Director, Healthcare Equity Research, Piper Sandler & Co.
Location: Virtual
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
For further information, please visit www.okyopharma.com.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com
